NCT06326359Not yet recruiting
Autologous Stromal Vascular Fraction in Treatment of Male Androgenic Alopecia
Evaluation of Safety and Efficacy of Autologous Stromal Vascular Fraction Derived From Denovo Versus Platelet Rich Plasma Enhanced Donner Site in Treatment of Male Androgenic Alopecia
In the register
This trial is not attached to a programme in the register yet. Unattached trials are kept on purpose: they are where new programmes turn up first.
What the registry records
- Status
- Not yet recruiting
- Declared phase
- Not applicable (NA in the registry)
- Sponsor
- Sohag University
- Participants (registry)
- 40
- Start
- March 2024 (planned)
- Primary completion
- October 2024
- Study completion
- October 2026
- Last registry update
- March 2024
- Countries
- —
Conditions studied: Androgenic Alopecia
Interventions: autologous stromal vascular fraction
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.